Concurrent sorafenib therapy extends the interval to subsequent TACE for patients with unresectable hepatocellular carcinoma.
about
Role of transarterial chemoembolization in relation with sorafenib for patients with advanced hepatocellular carcinoma.The safety and efficacy of transarterial chemoembolization combined with sorafenib and sorafenib mono-therapy in patients with BCLC stage B/C hepatocellular carcinoma.Can Kushen injection combined with TACE improve therapeutic efficacy and safety in patients with advanced HCC? a systematic review and network meta-analysis.What is the best combination treatment with transarterial chemoembolization of unresectable hepatocellular carcinoma? a systematic review and network meta-analysis.Sorafenib improves lipiodol deposition in transarterial chemoembolization of Chinese patients with hepatocellular carcinoma: a long-term, retrospective study.Transarterial chemoembolization plus sorafenib for the management of unresectable hepatocellular carcinoma: a systematic review and meta-analysis
P2860
Concurrent sorafenib therapy extends the interval to subsequent TACE for patients with unresectable hepatocellular carcinoma.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh
2016年學術文章
@zh-hant
name
Concurrent sorafenib therapy e ...... able hepatocellular carcinoma.
@en
type
label
Concurrent sorafenib therapy e ...... able hepatocellular carcinoma.
@en
prefLabel
Concurrent sorafenib therapy e ...... able hepatocellular carcinoma.
@en
P2093
P2860
P356
P1476
Concurrent sorafenib therapy e ...... able hepatocellular carcinoma.
@en
P2093
Dengzhong Liu
Huiying Zeng
Xuesong Yao
P2860
P304
P356
10.1002/JSO.24215
P577
2016-03-14T00:00:00Z